Acquired long QT syndrome in chronic kidney disease patients

References

• Patane S, Marte F, Di Bella G, et al. QT interval prolongation, torsade de pointes and renal disease. Int J Cardiol. 2008;130(2):e71–e73.
   PubMed Web of Science ®Google Scholar
• Familoni OB, Alebiosu CO, Ayodele OE. Effects and outcome of haemodialysis on QT intervals and QT dispersion in patients with chronic kidney disease. Cardiovasc J S Afr. 2006;17(1):19–23.
   PubMedGoogle Scholar
• Sherif KA, Abo-Salem E, Panikkath R, et al. Cardiac repolarization abnormalities among patients with various stages of chronic kidney disease. Clin Cardiol. 2014;37(7):417–421.
   PubMed Web of Science ®Google Scholar
• Nappi SE, Virtanen VK, Saha HH, et al. QTc dispersion increases during hemodialysis with low-calcium dialysate. Kidney Int. 2000;57(5):2117–2122.
   PubMed Web of Science ®Google Scholar
• Khosoosi Niaki MR, Saravi M, Oliaee F, et al. Changes in QT interval before and after hemodialysis. Caspian J Intern Med. 2013;4(1):590–594.
   PubMedGoogle Scholar
• Oktavia D, Nasution SA, Setiati S. The clinical factors’ prediction of increased intradialytic QT dispersion on the electrocardiograms of chronic hemodialysis patients. Saudi J Kidney Dis Transpl. 2013;24(2):274–280.
   PubMedGoogle Scholar
• Genovesi S, Rossi E, Nava M, et al. A case series of chronic haemodialysis patients: mortality, sudden death, and QT interval. Europace. 2013;15(7):1025–1033.
   PubMed Web of Science ®Google Scholar
• Liu P, Han D, Sun X, et al. Prevalence and risk factors of acquired long QT syndrome in hospitalized patients with chronic kidney disease. J Investig Med. 2019;67(2):289–294.
   PubMed Web of Science ®Google Scholar
• Naud J, Dumayne C, Nolin TD, et al. Drug pharmacokinetics in renal failure: What’s new? Nephrologie Therapeut. 2015;11(3):144–151.
   PubMed Web of Science ®Google Scholar
• Hage FG, de Mattos AM, Khamash H, et al. QT prolongation is an independent predictor of mortality in end-stage renal disease. Clin Cardiol. 2010;33(6):361–366.
   PubMed Web of Science ®Google Scholar
• Flueckiger P, Pastan S, Goyal A, et al. Associations of ECG interval prolongations with mortality among ESRD patients evaluated for renal transplantation. Ann Transpl. 2014;19:257–268.
   PubMed Web of Science ®Google Scholar
• Malik R, Waheed S, Parashara D, et al. Association of QT interval with mortality by kidney function: results from the National Health and Nutrition Examination Survey (NHANES). Open Heart. 2017;4(2):e000683.
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Rudser KD, Shlipak MG, et al. Kidney function, electrocardiographic findings, and cardiovascular events among older adults. Clin J Am Soc Nephrol. 2007;2(3):501–508.
   PubMed Web of Science ®Google Scholar
• Beaubien ER, Pylypchuk GB, Akhtar J, et al. Value of corrected QT interval dispersion in identifying patients initiating dialysis at increased risk of total and cardiovascular mortality. Am J Kidney Dis. 2002;39(4):834–842.
   PubMed Web of Science ®Google Scholar
• Luo S, Michler K, Johnston P, et al. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol. 2004;37 (Suppl):81–90.
   PubMedGoogle Scholar
• Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med. 2009;43(9):657–662.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, HHS. International conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist. 2005;70(202):61134–61135.
   PubMedGoogle Scholar
• Sohaib SM, Papacosta O, Morris RW, et al. Length of the QT interval: determinants and prognostic implications in a population-based prospective study of older men. J Electrocardiol. 2008;41(6):704–710.
   PubMed Web of Science ®Google Scholar
• Pasquier M, Pantet O, Hugli O, et al. Prevalence and determinants of QT interval prolongation in medical inpatients. Internal Med J. 2012;42(8):933–940.
   PubMed Web of Science ®Google Scholar
• Zhao J, Qi X, Hou F, et al. Prevalence, risk factors and in-hospital outcomes of QTc interval prolongation in liver cirrhosis. Am J Med Sci. 2016;352(3):285–295.
   PubMed Web of Science ®Google Scholar
• Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: role of the pharmacist in risk assessment, prevention and management. Can Pharm J. 2016;149(3):139–152.
   Web of Science ®Google Scholar
• Ayad RF, Assar MD, Simpson L, et al. Causes and management of drug-induced Long Qt Syndrome. Bayl Univ Med Cent Pro. 2010;23(3):250–255.
   PubMedGoogle Scholar
• Ikitimur B, Cosansu K, Karadag B, et al. Long-term impact of different immunosuppressive drugs on QT and PR intervals in renal transplant patients. Ann Noninvasive Electrocardiol. 2015;20(5):426–432.
   PubMed Web of Science ®Google Scholar
• Daya SK, Gowda RM, Khan IA. Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis. Am J Therap. 2004;11(1):77–79.
   PubMedGoogle Scholar
• Pham CP, de Feiter PW, van der Kuy PH, et al. Long QTc interval and torsade de pointes caused by fluconazole. Ann Pharmacother. 2006;40(7–8):1456–1461.
   PubMed Web of Science ®Google Scholar
• Vozniak JM, Jacobs JM. Vandetanib. J Adv Pract Oncol. 2012;3(2):112–116.
   PubMedGoogle Scholar
• Devkota A, Bakhit A, Dufresne A, et al. Arrhythmias and electrocardiographic changes in systolic heart failure. North Am J Med Sci. 2016;8(4):171–174.
   PubMed Web of Science ®Google Scholar
• Kolo PM, Opadijo OG, Omotoso AB, et al. Prevalence of QTc prolongation in adult Nigerians with chronic heart failure. West Afr J Med. 2008;27(2):69–73.
   PubMedGoogle Scholar
• Di Lullo L, Floccari F, Polito P. Right ventricular diastolic function in dialysis patients could be affected by vascular access. Nephron Clin Pract. 2011;118(3):c257–61.
   PubMedGoogle Scholar
• Akintunde AA, Oyedeji AT, Familoni OB, et al. QT Interval prolongation and dispersion: Epidemiology and clinical correlates in subjects with newly diagnosed systemic hypertension in Nigeria. J Cardiovasc Dis Res. 2012;3(4):290–295.
   PubMedGoogle Scholar
• Veglio M, Bruno G, Borra M, et al. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort. J Intern Med. 2002;251(4):317–324.
   PubMed Web of Science ®Google Scholar
• Ninkovic VM, Ninkovic SM, Miloradovic V, et al. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol. 2016;53(5):737–744.
   PubMed Web of Science ®Google Scholar
• Maule S, Veglio M, Mecca F, et al. Autonomic neuropathy and QT interval in hemodialysed patients. Clin Auton Res. 2004;14(4):233–239.
   PubMed Web of Science ®Google Scholar
• Cox AJ, Azeem A, Yeboah J, et al. Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the Diabetes Heart Study. Dia Care. 2014;37(5):1454–1461.
   PubMed Web of Science ®Google Scholar
• Kirvela M, Toivonen L, Lindgren L. Cardiac repolarization interval in end-stage diabetic and nondiabetic renal disease. Clin Cardiol. 1997;20(9):791–796.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Nagatani K, Otani N, et al. Electrocardiograph abnormalities in intracerebral hemorrhage. J Clin Neurosci. 2015;22(12):1959–1962.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao J, Wang H, et al. Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits. Am J Physiol Heart and Circulat Physiol. 2006;291(3):H1446–H1455.
   PubMed Web of Science ®Google Scholar
• van Noord C, van der Deure WM, Sturkenboom MC, et al. High free thyroxine levels are associated with QTc prolongation in males. J Endocrinol. 2008;198(1):253–260.
   PubMed Web of Science ®Google Scholar
• Li G, Cheng G, Wu J, et al. Drug-induced long QT syndrome in women. Adv Ther. 2013;30(9):793–802.
   PubMed Web of Science ®Google Scholar
• Kallergis EM, Goudis CA, Simantirakis EN, et al. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Scientific World J. 2012;2012:1–8.
   Google Scholar
• Di Iorio B, Bellasi A. QT interval in CKD and haemodialysis patients. Clin Kidney J. 2013;6(2):137–143.
   PubMedGoogle Scholar
• Schlit AF, Delaunois A, Colomar A, et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. Pharmacol Res Perspect. 2017;5(3):e00309.
   PubMed Web of Science ®Google Scholar
• Pickham D, Helfenbein E, Shinn JA, et al. High prevalence of corrected QT interval prolongation in acutely ill patients is associated with mortality: results of the QT in Practice (QTIP) Study. Crit Care Med. 2012;40(2):394–399.
   PubMed Web of Science ®Google Scholar
• Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–272.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Nagao M. Severity and multiplicity of microvascular complications are associated with QT interval prolongation in patients with type 2 diabetes. J Diabetes Investig. 2017;9(4):946–951.
   PubMed Web of Science ®Google Scholar
• Tarquini R, Lazzeri C, Pala L, et al. The diabetic cardiomyopathy. Acta Diabetol. 2011;48(3):173–181.
   PubMed Web of Science ®Google Scholar
• Lin YC, Huang J, Kan H, et al. Defective calcium inactivation causes long QT in obese insulin-resistant rat. Am J Physiol Heart Circulat Physiol. 2012;302(4):H1013–H1022.
   PubMed Web of Science ®Google Scholar
• Wu M, Obara Y, Norota I, et al. Insulin suppresses IKs (KCNQ1/KCNE1) currents, which require beta-subunit KCNE1. Pflugers Arch – Eur J Physiol. 2014;466(5):937–946.
   PubMed Web of Science ®Google Scholar
• Solanki JD, Gadhavi BP, Makwana AH, et al. Early screening of hypertension and cardiac dysautonomia in each hypertensive is needed-inference from a study of QTc interval in Gujarat, India. Int J Prev Med. 2018;9(1):62.
   PubMedGoogle Scholar
• Klimas J, Kruzliak P, Rabkin SW. Modulation of the QT interval duration in hypertension with antihypertensive treatment. Hypertens Res. 2015;38(7):447–454.
   PubMed Web of Science ®Google Scholar
• Piccirillo G, Germano G, Quaglione R, et al. QT-interval variability and autonomic control in hypertensive subjects with left ventricular hypertrophy. Clin Sci. 2002;102(3):363–371.
   PubMed Web of Science ®Google Scholar
• Marfella R, Gualdiero P, Siniscalchi M, et al. Morning blood pressure peak, QT intervals, and sympathetic activity in hypertensive patients. Hypertension. 2003;41(2):237–243.
   PubMed Web of Science ®Google Scholar
• Piccirillo G, Viola E, Nocco M, et al. Autonomic modulation and QT interval dispersion in hypertensive subjects with anxiety. Hypertension. 1999;34(2):242–246.
   PubMed Web of Science ®Google Scholar
• De Ambroggi L, Francia P, Ambroggi D. G. Repolarization abnormalities and arrhythmogenesis in hypertrophic myocardium. Anadolu Kardiyol Derg. 2007;7(Suppl 1):71–72.
   PubMedGoogle Scholar
• Bagshaw SM, Cruz DN, Aspromonte N, et al. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dial Transpl. 2010;25(5):1406–1416.
   PubMed Web of Science ®Google Scholar
• Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848.
   PubMed Web of Science ®Google Scholar
• Wettwer E, Amos GJ, Posival H, et al. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ Res. 1994;75(3):473–482.
   PubMed Web of Science ®Google Scholar
• Armoundas AA, Hobai IA, Tomaselli GF, et al. Role of sodium-calcium exchanger in modulating the action potential of ventricular myocytes from normal and failing hearts. Circulation Res. 2003;93(1):46–53.
   PubMed Web of Science ®Google Scholar
• Han D, Tan H, Sun C, et al. Dysfunctional Nav1.5 channels due to SCN5A mutations. Exp Biol Med. 2018;243(10):852–863.
   Web of Science ®Google Scholar
• Undrovinas A, Maltsev VA. Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart. Cardiovasc Hematol Agents Med Chem. 2008;6(4):348–359.
   PubMedGoogle Scholar
• Tisdale JE, Overholser BR, Wroblewski HA, et al. Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction. J Clin Pharmacol. 2012;52(9):1296–1305.
   PubMed Web of Science ®Google Scholar
• Lekawanvijit S. Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome. Toxins. 2018;110(9):352.
   Google Scholar
• Mozos I, Costea C, Serban C, et al. Factors associated with a prolonged QT interval in liver cirrhosis patients. J Electrocardiol. 2011;44(2):105–108.
   PubMed Web of Science ®Google Scholar
• Crisan TO, Cleophas MC, Oosting M, et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2016;75(4):755–762.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Post WS, Dalal D, et al. Serum 25-hydroxyvitamin D, calcium, phosphorus, and electrocardiographic QT interval duration: findings from NHANES III and ARIC. J Clin Endocrinol Metab. 2011;96(6):1873–1882.
   PubMed Web of Science ®Google Scholar
• Palmeri NO, Davidson KW, Whang W, et al. Parathyroid hormone is related to QT interval independent of serum calcium in patients with coronary artery disease. Ann Noninvasive Electrocardiol. 2018;23(2):e12496.
   PubMed Web of Science ®Google Scholar
• Ebisawa K, Kimura K, Nakayama T, et al. Cardiac electrophysiologic effects of parathyroid hormone in the guinea pig. Heart Vessels. 1995;10(3):128–137.
   PubMed Web of Science ®Google Scholar
• Hu MC, Shi M, Cho HJ, et al. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol. 2015;26(6):1290–1302.
   PubMed Web of Science ®Google Scholar
• Xie J, Yoon J, An SW, et al. Soluble Klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol. 2015;26(5):1150–1160.
   PubMed Web of Science ®Google Scholar
• Gao H, Liu S. Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease. Life Sci. 2017;185:23–29.
   PubMed Web of Science ®Google Scholar
• Ozportakal H, Ozkok A, Alkan O, et al. Hemodialysis-induced repolarization abnormalities on ECG are influenced by serum calcium levels and ultrafiltration volumes. Int Urol Nephrol. 2017;49(3):509–515.
   PubMed Web of Science ®Google Scholar
• Karmin O, Siow YL. Metabolic imbalance of homocysteine and hydrogen sulfide in kidney disease. Curr Med Chem. 2018;25(3):367–377.
   PubMed Web of Science ®Google Scholar
• Li Z, Guo X, Sun G, et al. Plasma homocysteine levels associated with a corrected QT interval. BMC Cardiovasc Disord. 2017;17(1):182.
   PubMedGoogle Scholar
• Rosenberger D, Gargoum R, Tyagi N, et al. Homocysteine enriched diet leads to prolonged QT interval and reduced left ventricular performance in telemetric monitored mice. Nutr Metab Cardiovasc Dis. 2011;21(7):492–498.
   PubMed Web of Science ®Google Scholar
• Gilligan S, Raphael KL. Hyperkalemia and hypokalemia in CKD: prevalence, risk factors, and clinical outcomes. Adv Chronic Kidney Dis. 2017;24(5):315–318.
   PubMed Web of Science ®Google Scholar
• Weiss JN, Qu Z, Shivkumar K. Electrophysiology of hypokalemia and hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10(3):pii:e004667.
   Web of Science ®Google Scholar
• Hwang JC, Wang CT, Chen CA, et al. Hypokalemia is associated with increased mortality rate in chronic hemodialysis patients. Blood Purif. 2011;32(4):254–261.
   PubMed Web of Science ®Google Scholar
• Abuelo JG. Low dialysate potassium concentration: an overrated risk factor for cardiac arrhythmia? Semin Dial. 2015;28(3):266–275.
   PubMed Web of Science ®Google Scholar
• Floege J. Magnesium in CKD: more than a calcification inhibitor? J Nephrol. 2015;28(3):269–277.
   PubMed Web of Science ®Google Scholar
• Dhein S, Muller A, Gerwin R, et al. Comparative study on the proarrhythmic effects of some antiarrhythmic agents. Circulation. 1993;87(2):617–630.
   PubMed Web of Science ®Google Scholar
• Vandael E, Vandenberk B, Vandenberghe J, et al. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16–25.
   PubMed Web of Science ®Google Scholar
• Eryol NK, Çolak R, Özdoğru b, et al. Effects of calcium treatment on QT interval and QT dispersion in hypocalcemia. Am J Cardiol. 2003;91(6):750–752.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34(4):381–390.
   PubMed Web of Science ®Google Scholar
• Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality. Kidney Int. 2011;79(2):250–257.
   PubMed Web of Science ®Google Scholar
• Kuipers J, Verboom LM, Ipema KJR, et al. the prevalence of intradialytic hypotension in patients on conventional hemodialysis: a systematic review with meta-analysis. Am J Nephrol. 2019;49(6):497–506.
   PubMed Web of Science ®Google Scholar
• Stefansson BV, Brunelli SM, Cabrera C, et al. Intradialytic hypotension and risk of cardiovascular disease. Clin J Am Soc Nephrol. 2014;9(12):2124–2132.
   PubMed Web of Science ®Google Scholar
• Zuidema MY, Dellsperger KC. Myocardial stunning with hemodialysis: clinical challenges of the cardiorenal patient. Cardiorenal Med. 2012;2(2):125–133.
   PubMed Web of Science ®Google Scholar
• McIntyre CW, Harrison LE, Eldehni MT, et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(1):133–141.
   PubMed Web of Science ®Google Scholar
• Numaga-Tomita T, Oda S, Shimauchi T, et al. TRPC3 channels in cardiac fibrosis. Front Cardiovasc Med. 2017;4:56–56.
   PubMed Web of Science ®Google Scholar
• Everett RJ, Stirrat CG, Semple SI, et al. Assessment of myocardial fibrosis with T1 mapping MRI. Clin Radiol. 2016;71(8):768–778.
   PubMed Web of Science ®Google Scholar
• Rutherford E, Talle MA, Mangion K, et al. Defining myocardial tissue abnormalities in end-stage renal failure with cardiac magnetic resonance imaging using native T1 mapping. Kidney Int. 2016;90(4):845–852.
   PubMed Web of Science ®Google Scholar
• Clyne N, Hellberg M, Kouidi E, et al. Relationship between declining glomerular filtration rate and measures of cardiac and vascular autonomic neuropathy. Nephrology. 2016;21(12):1047–1055.
   PubMed Web of Science ®Google Scholar
• Snitker S, Doerfler RM, Soliman EZ, et al. Association of QT-prolonging medication use in CKD with electrocardiographic manifestations. Clin J Am Soc Nephrol. 2017;12(9):1409–1417.
   PubMed Web of Science ®Google Scholar
• Cashion AK, Hathaway DK, Milstead EJ, et al. Changes in patterns of 24-hr heart rate variability after kidney and kidney-pancreas transplant. Transplantation. 1999;68(12):1846–1850.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Sever MS, Demirel S, et al. Improvement of uremic autonomic dysfunction after renal transplantation: a heart rate variability study. Nephron. 1998;80(1):57–60.
   PubMed Web of Science ®Google Scholar
• Monfared A, Atrkar Roshan Z, Salari A, et al. QT intervals in patients receiving a renal transplant. Exp Clin Transplant. 2012;10(2):105–109.
   PubMed Web of Science ®Google Scholar
• Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Therap Adv Psychopharmacol. 2017;7(12):251–264.
   PubMed Web of Science ®Google Scholar
• Shetty N, Gupta S. Eribulin drug review. South Asian J Cancer. 2014;3(1):57–59.
   PubMedGoogle Scholar
• Richard F. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21(12):1468–1472.
   PubMed Web of Science ®Google Scholar
• Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation. 2010;121(8):1047–1060.
   PubMed Web of Science ®Google Scholar
• Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation. 1997;96(7):2149–2154.
   PubMed Web of Science ®Google Scholar
• Othong R, Devlin JJ, Kazzi ZN. Medical toxicologists’ practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region. Clin Toxicol. 2015;53(4):204–209.
   Web of Science ®Google Scholar
• Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol. 2006;48(5):e247–e346.
   PubMed Web of Science ®Google Scholar
• Banai S, Tzivoni D. Drug therapy for torsade de pointes. J Cardiovasc Electrophysiol. 1993;4(2):206–210.
   PubMed Web of Science ®Google Scholar
• Kaye P, O’Sullivan I. The role of magnesium in the emergency department. EMJ. 2002;19(4):288–291.
   Google Scholar
• Tan HL, Hou CJ, Lauer MR, et al. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med. 1995;122(9):701–714.
   PubMed Web of Science ®Google Scholar
• Omar HR, Sprenker C, Karlnoski R, et al. The use of isoproterenol and phenytoin to reverse torsade de pointes. Am J Emerg Med. 2014;32(6):683.e5–683.e7.
   Web of Science ®Google Scholar
• Rajpal S, Mundi AS, Reddy PC, et al. Treatment of methadone-induced torsades de pointes with lidocaine. J Louisiana State Medical Soc. 2013;165(6):338–341.
   PubMedGoogle Scholar
• Badri M, Patel A, Patel C, et al. Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures. JACC Clin Electrophysiol. 2015;1(4):315–322.
   PubMedGoogle Scholar
• Charlton NP, Lawrence DT, Brady WJ, et al. Termination of drug-induced torsades de pointes with overdrive pacing. Am J Emerg Med. 2010;28(1):95–102.
   PubMed Web of Science ®Google Scholar
• Chadda KR, Jeevaratnam K, Lei M, et al. Sodium channel biophysics, late sodium current and genetic arrhythmic syndromes. Pflugers Arch – Eur J Physiol. 2017;469(5–6):629–641.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang L. The role of mexiletine in the management of long QT syndrome. J Electrocardiol. 2018;51(6):1061–1065.
   PubMed Web of Science ®Google Scholar
• Wu L, Ma J, Li H, et al. Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation. 2011;123(16):1713–1720.
   PubMed Web of Science ®Google Scholar